EMA consults on regulatory acceptance of "3R" alternatives to animal studies
This article was originally published in SRA
Executive Summary
The European Medicines Agency is seeking stakeholder feedback concerning the revision of its position on the replacement of animal studies with alternative models for drug testing1,2. The exercise, it is expected, will lead to the development of a clear process for the regulatory acceptance of all "3R" (replacement, reduction and refinement) alternative methods for non-clinical testing of medicinal products.